Article Versions Notes

Bownes LV, Marayati R, Quinn CH, Beierle AM, Hutchins SC, Julson JR, Erwin MH, Stewart JE, Mroczek-Musulman E, Ohlmeyer M, et al. Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma. Cancers. 2022; 14(8):1952. https://doi.org/10.3390/cancers14081952

Bownes, Laura V., Raoud Marayati, Colin H. Quinn, Andee M. Beierle, Sara C. Hutchins, Janet R. Julson, Michael H. Erwin, Jerry E. Stewart, Elizabeth Mroczek-Musulman, Michael Ohlmeyer, and et al. 2022. "Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma" Cancers 14, no. 8: 1952. https://doi.org/10.3390/cancers14081952

Bownes, L. V., Marayati, R., Quinn, C. H., Beierle, A. M., Hutchins, S. C., Julson, J. R., Erwin, M. H., Stewart, J. E., Mroczek-Musulman, E., Ohlmeyer, M., Aye, J. M., Yoon, K. J., & Beierle, E. A. (2022). Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma. Cancers, 14(8), 1952. https://doi.org/10.3390/cancers14081952